Low dose naltrexone (LDN) is not addictive. It has no potential for abuse, does not produce euphoria, and does not activate the brain’s reward system the way addictive substances do. In fact, naltrexone does the opposite: it blocks opioid receptors rather than stimulating them, which is why it’s used as a treatment for addiction itself.
Why LDN Cannot Produce Addiction
Addictive drugs work by flooding opioid receptors or the brain’s reward circuitry with feel-good signals. Naltrexone is an opioid receptor antagonist, meaning it sits on those receptors and prevents them from being activated. It doesn’t trigger euphoria, doesn’t release dopamine in the reward pathway, and doesn’t create the reinforcing “high” that drives compulsive drug-seeking behavior. This is true at every dose, whether the standard 50 mg used for addiction treatment or the 1 to 5 mg range used in LDN.
The Drug Enforcement Administration removed naltrexone from all controlled substance schedules in 1975 after determining it has no potential for abuse. It remains unscheduled today, which means the federal government considers it to carry zero risk of dependence or misuse.
How LDN Differs From Standard Naltrexone
Standard naltrexone is FDA-approved at 50 mg or higher for treating opioid and alcohol use disorders. At that dose, it heavily blocks opioid receptors around the clock, preventing alcohol or opioids from producing their rewarding effects.
LDN uses a fraction of that dose, typically 1 to 5 mg. At these low levels, the drug only partially and briefly blocks opioid receptors. The theory behind LDN is that this short blockade prompts the body to temporarily increase its own production of natural pain-relieving chemicals. LDN is not FDA-approved as a standalone treatment; it is prescribed off-label for conditions like fibromyalgia, chronic pain, and certain autoimmune disorders.
No Evidence of Tolerance Buildup
One hallmark of addictive substances is tolerance: you need more and more to get the same effect. Clinical use of LDN does not show this pattern. In fibromyalgia studies lasting up to 14 months, patients stayed on stable doses without needing escalation. When doses are increased during the initial phase, it follows a planned titration schedule, not a response to diminishing effects. Some patients actually need to slow down the titration if they’re sensitive to the drug, which is the opposite of what you’d see with a tolerance-building substance.
Side Effects Are Mild, Not Withdrawal-Related
Across multiple fibromyalgia studies, no severe adverse events were reported with LDN use. The most common side effects were mild and temporary: vivid dreams, brief insomnia, headache, occasional nausea, and in some cases fatigue or diarrhea. These could often be reduced simply by lowering the dose. Two studies reported no side effects at all. None of these effects resemble withdrawal symptoms, and stopping LDN does not produce the kind of rebound or withdrawal syndrome associated with addictive medications.
The One Serious Risk: Opioid Interactions
While LDN itself carries no addiction risk, it does pose a real danger if taken alongside opioid medications. Because naltrexone blocks opioid receptors, taking it while your body still depends on opioids can trigger precipitated withdrawal. This is not a sign of naltrexone addiction. It’s a reaction caused by suddenly stripping opioids off receptors that have become dependent on them.
Precipitated withdrawal can be severe. Symptoms can appear within five minutes and last up to 48 hours, including intense nausea, vomiting, diarrhea, confusion, and in some cases hallucinations. Post-marketing reports have documented cases serious enough to require hospitalization and intensive care. Anyone currently taking opioid medications (including tramadol, buprenorphine, or methadone) needs to be completely opioid-free for at least 7 to 10 days before starting naltrexone. People transitioning from longer-acting opioids like methadone may need to wait two weeks or more.
This interaction risk is about the opioids already in your system, not about naltrexone creating dependence. Once you’re opioid-free, LDN itself does not produce physical dependence, cravings, or any compulsion to continue using it.